Business context and reporting period
Retractable Technologies, Inc. designs, manufactures and markets safety syringes and other medical products. This unaudited Form 10-Q covers the three months ended March 31, 2024; comparisons are with the three months ended March 31, 2023 unless stated otherwise.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior balance-sheet date |
|---|---|---|
| Net sales | $7.60 million | $11.00 million |
| Gross profit (gross margin) | $1.90 million (25.0%) | $2.87 million (26.1%) |
| Operating expenses | $4.89 million | $5.61 million |
| Operating loss | $(2.99) million | $(2.74) million |
| Net income | $429,000 | $991,000 |
| Net income applicable to common shareholders; EPS | $372,000; $0.01 | $933,000; $0.03 |
| Cash used by operating activities | $(2.02) million | $(3.70) million |
| Cash and cash equivalents | $10.01 million | $12.67 million at Dec. 31, 2023 |
| Investments in debt and equity securities | $36.63 million | $34.62 million at Dec. 31, 2023 |
| Total debt | $1.46 million | $1.54 million at Dec. 31, 2023 |
Operating cash use reflected working-capital movements, including a $3.25 million reduction in receivables, a $1.91 million inventory increase, and a $2.18 million decrease in accounts payable. Investing activities used $503,000, including capital purchases and securities purchases; financing activities used $131,000, primarily for debt repayment and preferred dividends.
Total assets were $175.98 million and total liabilities were $76.32 million at March 31, 2024. Current assets were $75.71 million versus current liabilities of $6.87 million. Other long-term liabilities, largely deferred TIA funding, were $68.29 million. The company recorded $1.48 million of TIA-related income in the quarter. Investments were 20.8% of total assets and included $4.01 million of cumulative unrealized losses on equity securities at quarter-end.
Material changes versus prior period
- Sales fell 30.9%, while total unit sales declined 48.2%. Domestic revenue rose 22.5% and domestic unit sales rose 18.3%; international revenue declined approximately 82.8%, mainly due to fewer vaccination-related sales.
- The geographic mix shifted: U.S. sales were 87.4% of revenue, compared with 49.3% a year earlier. North and South American sales excluding the U.S. fell from $4.77 million to $155,000; other international sales were broadly flat.
- Gross profit declined by $969,000. Lower operating expenses, down 12.9%, did not offset the gross-profit decline, and the operating loss widened by $246,000.
- Net income declined despite the $1.73 million unrealized investment gain and $1.48 million of TIA income. The prior-year period also included a $746,000 gain on sale of equity securities.
- Cash decreased by $2.66 million from year-end, while investments increased by $2.01 million. Inventory increased by $1.91 million.
Outlook, risks, contingencies and unusual items
- Management expects adequate resources to meet short-term needs for at least 12 months from issuance of the financial statements, citing cash, operating income and investments available for sale. It also states that currently foreseeable long-term liquidity needs are manageable. No revenue or earnings guidance is provided.
- Management attributes weaker domestic demand in part to customers retaining COVID-vaccination syringe inventory; timing of future international orders is uncertain. The company says COVID-era government orders are not indicative of future operations.
- China sourcing is a significant exposure: Chinese manufacturers produced approximately 90.4% of products in Q1 2024. A May 14, 2024 trade announcement identified a 50% tariff on syringes and needles, likely effective in Q3 2024. The company may need to increase domestic production or seek alternative sourcing if China purchases are no longer economical.
- Other stated risks include demand changes, tariffs and supplier costs, manufacturing and foreign-trade risks, access to markets, patent protection, competition, and the ability to maintain liquidity. Management notes that cost increases may not be recoverable through price increases.
- On February 5, 2024, the company initiated a voluntary recall of 477,600 EasyPoint Needle units from a specified lot due to possible needle detachment that could cause serious injury. The company was determining how many units remained unused and estimated potential recall expense at approximately $116,000.
- The company’s lawsuit against Locke Lord, LLP and Roy Hardin alleges legal malpractice and negligence relating to prior litigation. A motion for summary judgment was denied in May 2024; no new trial date had been set.
- Approximately $1.4 million of dividends remains payable to about 90 former preferred shareholders whom the company has not yet contacted. Estimated unclaimed distributor pricing credits from prior purchases were $1.6 million at quarter-end.
- The TIA successor agreement runs through June 30, 2030 and includes equipment maintenance, capacity availability and U.S. government preference during a public health emergency. The company says no further TIA expansion reimbursements are expected.
Important facts for investors to verify
- Whether domestic demand can offset continued weakness in international and vaccination-related sales, and the timing and scale of future international orders.
- The effective scope and timing of the announced China tariffs, potential cost pass-through, and the feasibility and cost of domestic production or alternative sourcing.
- The ultimate number of recalled units, recall costs and any related regulatory or customer consequences.
- Investment portfolio values and volatility, given the portfolio’s material share of assets and the quarter’s reliance on unrealized investment gains for reported net income.
- Cash generation and working-capital trends, including inventory levels, distributor credits and dividend obligations.